Eliaz Therapeutics Inc

Eliaz Therapeutics (ETI) was founded in 2015 by Isaac Eliaz, MD to leverage his significant expertise in Galectin-3 and Apheresis to develop and commercialize a therapeutic Apheresis device that removes Galectin-3 from the blood. Galectin-3 has a causal role in many life-threatening inflammatory and fibrotic diseases, immune dysregulation (including the cytokine storm), kidney deterioration and cancer that do not have effective treatments today. The initial indication will be Sepsis and Sepsis induced Acute Kidney Injury (AKI). AKI is a sudden decrease in kidney function with or without kidney damage, occurring over a few hours or days. Annual US hospitalizations for AKI are in excess of 4,000,000 and deaths exceed 500,000. Diabetes, hypertension, and advanced age are primary risk factors for sepsis and acute kidney injury. It is increasingly recognized as an in-hospital complication of sepsis, heart conditions, surgery and Covid-19. Its most severe stage requires treatment with dialysis or renal transplant therapy. Acute kidney injury is also associated with higher likelihood of long-term care, incidence of chronic kidney disease and hospital mortality, and higher long-term health care costs. Currently, there are no approved treatments to prevent, interrupt, or hasten recovery from sepsis and sepsis-AKI. XGAL3 apheresis has the potential to do all three and thus exert a dramatic impact on sepsis patient management and outcomes, potentially saving hundreds of thousands of lives per year.